Biotest
Biotest GmbH & Co. KGaA is a German plasma-derived biopharmaceutical company developing and manufacturing therapeutics for hematology, clinical immunology, and intensive care medicine, serving hospitals and specialty clinics across Europe and, via licensing partner Kedrion, the US.
- Company typePublic
- Founded1946
- HeadquartersDreieich, Germany
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Biotest does
Biotest GmbH & Co. KGaA is a German plasma-derived biopharmaceutical company founded in 1946 and headquartered in Dreieich, Germany. It develops, manufactures, and commercializes therapeutics across three core therapy areas: hematology (bleeding disorders such as hemophilia A and B, via Haemoctin SDH and Haemonine), clinical immunology (primary immunodeficiencies, immune thrombocytopenia, and hyperimmune conditions, via Yimmugo, Intratect, Cytotect CP, Hepatect CP, Varitect CP, and Zutectra), and intensive care medicine (severe infections, coagulation disorders, and volume/protein substitution, via Albiomin, Biseko, Cofact, Pentaglobin, and Prufibry). The company's underlying technology is plasma fractionation and purification from human plasma, with proprietary production processes yielding differentiated compositions such as IgM-enriched Pentaglobin and the novel IgM/IgA/IgG Trimodulin (BT588). An industrial human serum albumin product is also sold to biopharmaceutical manufacturers as a GMP-grade excipient.
Biotest's pipeline is anchored by Trimodulin (Phase III ESsCAPE study for severe community-acquired pneumonia), Yimmugo / IgG Next Generation (BT595, approved in Germany, Austria, and UK with further approvals ongoing), and Fibrinogen / Prufibry / Fesilty (BT524, approved and launched). The Biotest Next Level manufacturing facility is under development to scale Yimmugo production. Since 2017, Biotest has been majority-owned by Spanish plasma major Grifols, which provides plasma sourcing, distribution leverage, and capital backing, while Biotest retains its own listed-company governance (Frankfurt Stock Exchange ticker BIO; legal form changed from AG to GmbH & Co. KGaA in 2023). The company distributes prescription-based plasma products directly to hospitals, specialty clinics, and intensive care units through dedicated ordering systems in Germany and via international channels, with US commercialization of Yimmugo licensed to Kedrion Biopharma under a partnership announced in October 2025 following FDA approval in 2024. Biotest's revenue is not disclosed in the source data; the company employs 1,001–5,000 people across operations in Germany, Austria, Switzerland, and Hungary, with its website currently restricted to German users.
Biotest firmographics
Firmographics- Name
- Biotest
- Legal name
- Biotest GmbH & Co. KGaA
- Website
- https://biotest.com
- Company type
- Public
- Founded year
- 1946
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Biotest GmbH & Co. KGaA is a German plasma-derived biopharmaceutical company developing and manufacturing therapeutics for hematology, clinical immunology, and intensive care medicine, serving hospitals and specialty clinics across Europe and, via licensing partner Kedrion, the US.
- Ownership category
- akta.pro rank
Biotest industry classification
Industry- Product category
- Plasma-derived biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Plasma-Derived Therapeutics (immunoglobulins, albumin, clotting factors) (HLAAAAAI)
- akta.pro secondary industries
- Plasma Fractionation & Purification Manufacturing (HLAIAHAI), Hyperimmune (Specific) Immunoglobulins (e.g., Anti-D, Tetanus, Rabies, Hep B) (HLAIAHAE), Immunoglobulins & Passive Immunization Biologics (IVIG, hyperimmune globulins, antitoxins) (HLAAAEAH), Blood Factors & Hemostasis Biologics (recombinant clotting factors, thrombolytics) (HLAAAAAL), Hematology Specialty Pharmaceuticals (Non-malignant) (HLAIACAI)
Keywords
Where Biotest is headquartered
LocationHeadquarters
- HQ city
- Dreieich
- HQ country
- Germany
- HQ region
- Europe
Offices4 records
Markets served
Biotest business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Technology or R&D, Personnel, Infrastructure, Marketing or Sales
Revenue model
- Plasma-derived pharmaceuticals: Sale of plasma-derived therapeutic products including immunoglobulins for clinical immunology, albumin and other proteins for intensive care medicine, and coagulation factors for hematology. Products are sold to hospitals, clinics, and healthcare institutions through direct prescription-based channels.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
Biotest product offering
Product offeringCore offering
Biotest develops, manufactures, and sells plasma-derived therapeutic proteins for haematology, clinical immunology, and intensive care medicine. Its product range includes immunoglobulins (polyvalent and hyperimmune), coagulation factor concentrates for haemophilia and fibrinogen deficiency, human albumin and plasma protein solutions for critical care, and an industrial GMP-grade human serum albumin for biopharmaceutical excipient use. Products are sold as prescription pharmaceuticals to hospitals, specialty clinics, intensive care units, and biopharmaceutical manufacturers, primarily through direct institutional sales.
Product overview
Biotest is a plasma-derived biopharmaceutical company offering a diversified portfolio of products across three therapeutic areas: Haematology (Haemoctin® SDH, Haemonine® for Haemophilia A and B treatment), Clinical Immunology (Yimmugo®, Cytotect® CP, Hepatect® CP, Varitect® CP, Intratect®, Zutectra® for antibody deficiencies and viral infections), and Intensive Care Medicine (Albiomin®, Biseko®, Cofact®, Pentaglobin®, Prufibry® for volume replacement, coagulation disorders, and severe infections). The company also supplies Biotest Human Serum Albumin for industrial/biotech applications. The pipeline includes Trimodulin (BT588) for severe community-acquired pneumonia, IgG Next Generation/Yimmugo (BT595) for PID and ITP, and Fibrinogen/Prufibry/Fesilty (BT524) for fibrinogen deficiency, all in various clinical development phases.
Differentiator
Problem solved
Functional benefit
Brands
- Biotest Next Level: New manufacturing facility under development for production of IgG Next Generation / Yimmugo products.
Products and services
- Haemoctin SDH
Quantifiable outcome
- Trimodulin may prevent progression of severe community-acquired pneumonia, including the need for invasive mechanical ventilation and other intensive care procedures
- +1 more outcomes
Companies that use Biotest
Customer profileSegments4 records
Ideal customer profiles2 records
Biotest technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Biotest partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Kedrion BiopharmamajorLicensing and commercialization agreement for Yimmugo immunoglobulin therapy. Kedrion Biopharma commercialized Yimmugo in the US market under FDA approval obtained in 2024. The product is an innovation in immunoglobulin treatment catering to over 500,000 people in the US affected by primary immunodeficiency.
Scale indicators2 records
Recent moves7 records
Expansion highlights6 records
Biotest competitors and assessment
Company assessmentRegional players
- China Biologic Products Holdings: Chinese plasma-derived therapeutics producer manufacturing albumin, immunoglobulins, and coagulation factors. Regional peer with comparable plasma fractionation business model primarily serving the Chinese market.
- Sanquin Plasma Products: Dutch blood supply foundation with a plasma products division manufacturing immunoglobulins, coagulation factors, and albumin. Comparable plasma fractionation business primarily serving the Netherlands and selected European markets.
- Bio Products Laboratory (BPL): UK-based plasma fractionator producing immunoglobulins (Gammaplex, Vigam), albumin, and coagulation factors. Comparable mid-sized plasma therapeutics player with focus on UK and selected international markets.
Direct peers
- Octapharma: Swiss-headquartered global plasma fractionator offering immunoglobulins (Octagam, Octanate), coagulation factors, and albumin. Direct competitor in plasma-derived therapeutics with comparable mid-sized scale and European manufacturing footprint.
- Takeda Pharmaceutical Company (Plasma-Derived Therapies): Takeda's Plasma-Derived Therapies division (formerly Shire/Baxalta) markets immunoglobulins (Gammagard, Hyqvia) and albumin globally. Direct competitor in IVIG and specialty plasma products with broader therapeutic area reach and larger commercial infrastructure.
- Kedrion Biopharma: Italian plasma-derived therapeutics company producing immunoglobulins, coagulation factors, and albumin. Direct peer in plasma fractionation and current US distribution partner for Biotest's Yimmugo, making it both a competitor and partner in specific markets.
- CSL Behring: CSL Behring is the global leader in plasma-derived therapeutics, producing immunoglobulins (Privigen, Hizentra), albumin, and coagulation factors. Directly competes with Biotest across all three therapy areas (hematology, immunology, intensive care) with significantly larger scale and broader geographic reach.
- LFB (Laboratoire français du Fractionnement et des Biotechnologies): French state-linked plasma fractionator producing immunoglobulins (Tegeline, Clairyg), coagulation factors, and albumin. Direct competitor in plasma-derived therapeutics with similar European focus and comparable mid-market positioning.
Emerging players
- ADMA Biologics: US-focused plasma-derived immunoglobulin company marketing ASCENIV, BIVIGAM, and Nabi-HB for primary immunodeficiency and hepatitis B. Smaller-scale emerging competitor with similar focus on specialty plasma-derived immunoglobulins and hyperimmune products.
Broad incumbents
- Grifols: Spanish plasma therapeutics giant and Biotest's majority shareholder. Competes across the same plasma product categories (immunoglobulins, albumin, coagulation factors, hyperimmunes) at substantially larger global scale with the world's largest plasma collection network.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Biotest social profiles
Digital presenceBiotest financial estimates
Financial estimateRevenue estimate
Valuation estimate
Biotest leadership team
Management profileNumber of profiles
Profiles7 records
Biotest subsidiaries and ownership
Company hierarchySubsidiaries3 records
Biotest funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Biotest M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Biotest
What does Biotest do?
Biotest develops, manufactures, and sells plasma-derived therapeutic proteins for haematology, clinical immunology, and intensive care medicine. Its product range includes immunoglobulins (polyvalent and hyperimmune), coagulation factor concentrates for haemophilia and fibrinogen deficiency, human albumin and plasma protein solutions for critical care, and an industrial GMP-grade human serum albumin for biopharmaceutical excipient use. Products are sold as prescription pharmaceuticals to hospitals, specialty clinics, intensive care units, and biopharmaceutical manufacturers, primarily through direct institutional sales.
Is Biotest a public or private company?
Biotest is a public company. It is classified as corporate owned and is currently operating.
When was Biotest founded?
Biotest was founded in 1946. It employs 1,001 to 5,000 people.
Where is Biotest based?
Biotest is headquartered in Dreieich, Germany, in the Europe region.
How does Biotest make money?
One revenue line is on record: plasma-derived pharmaceuticals.
Who are Biotest's main competitors?
Regional players on record are China Biologic Products Holdings, Sanquin Plasma Products and Bio Products Laboratory (BPL). Direct peers are Octapharma, Takeda Pharmaceutical Company (Plasma-Derived Therapies), Kedrion Biopharma, CSL Behring and LFB (Laboratoire français du Fractionnement et des Biotechnologies). ADMA Biologics is listed as an emerging player. Grifols is listed as a broad incumbent.
Does Biotest have an API?
No public API is recorded for Biotest.
What industry is Biotest in?
Biotest's product category is Plasma-derived biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAI, Plasma-Derived Therapeutics (immunoglobulins, albumin, clotting factors), with a secondary code of HLAIAHAI, Plasma Fractionation & Purification Manufacturing. Its NAICS code is 325414 and its SIC code is 2836.